Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

<p>Abstract</p> <p>Background</p> <p>Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30–40% of ER+BC will relaps...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daidone Maria G, Reid James F, Ellis Paul, Ryder Kenneth, Gillet Cheryl, Tutt Andrew M, Lallemand Françoise, Wirapati Pratyaksha, Desmedt Christine, Haibe-Kains Benjamin, Loi Sherene, Pierotti Marco A, Berns Els MJJ, Jansen Maurice PHM, Foekens John A, Delorenzi Mauro, Bontempi Gianluca, Piccart Martine J, Sotiriou Christos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2008-05-01
Colecção:	BMC Genomics
Acesso em linha:	http://www.biomedcentral.com/1471-2164/9/239
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!